Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

A randomized, double blind placebo controlled 20 week study of two doses of Semaglutide(SEMA) versus placebo in men and women with AUD and obesity (OB:BMI 30‐49.9 kg/m2) willbe studied to assess alcohol and food craving and stress in a validated laboratory modelas well as examine changes in alcohol intake and related alcohol use outcomes during a 20week clinical treatment and 8 week post‐treatment follow‐up phase of the study, in orderto test mechanisms by which SEMA may exerts significant effects on alcohol use disorderoutcomes.